2023
DOI: 10.1002/pros.24663
|View full text |Cite
|
Sign up to set email alerts
|

A prospective, randomized, open‐label, parallel trial comparing the efficacy of α‐blocker or 5α‐reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia

Kwang Suk Lee,
Jeong Woo Yoo,
Dae Ho Kim
et al.

Abstract: BackgroundIt is uncertain how long combination therapy should be continued in patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). We investigated the withdrawal effects of α1‐adrenergic receptor blocker (AB) or 5α‐reductase inhibitor (5ARI) following successful combination therapy.MethodsThis prospective, randomized, open‐label, parallel trial enrolled 222 patients with BPH/LUTS who showed at least a seven‐point improvement in International Prostate Symptom Score‐total (IP… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 19 publications
0
0
0
Order By: Relevance